Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Trial Profile

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Uridine triacetate (Primary)
  • Indications Orotic aciduria
  • Focus Therapeutic Use
  • Sponsors Wellstat Therapeutics Corporation
  • Most Recent Events

    • 24 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 11 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 04 Sep 2015 The US FDA has approved uridine triacetate (Xuriden) for the treatment of patients with hereditary orotic aciduria, according to an FDA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top